The rate of people who can't afford needed health care is at the lowest rate in 16 years.» Read More
The CDC said doctors and state health officials should be on the lookout for people infected with the H5N2 bird flu virus, NBC reports.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
The figures are in: HealthCare.gov has about 6.4 million paying customers who are at risk of losing subsidies in a pending Supreme Court case.
South Korea confirmed five more cases of Middle East Respiratory Syndrome (MERS), bringing to 30 the number of infected people. Two people have died.
Many of the proposed rate increases of 10 percent or more for Obamacare health insurance plans have been revealed.
Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.
As a stock market analyst, Janet Yellen makes a pretty good Federal Reserve chair.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
The "Halftime Report" traders give their trades for the second half.
Proposals to deal with a potential Supreme Court ruling could merely delay serious disruption to the insurance market.
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.
Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.
Millions of people could suffer if the Supreme Court strikes down Obamacare subsidies, two doctors tell CNBC.
CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.
CNBC's Meg Tirrell, and Daniel O'Day, Roche Pharmaceuticals COO, talk about the the encouraging results in treating lung cancer and using precision medicines to personalize treatment.
Get the best of CNBC in your inbox